REGENXBIO Q3 2026 revenue falls to $9.2M; loss narrows
The $251.0 million September balance, together with $39.0 million in October settlement proceeds, is expected to fund operations into late Q4 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
REGENXBIO Inc. reported third-quarter 2026 revenue of $9.2 million, compared with $29.7 million a year earlier, and a net loss of $40.7 million, versus $61.9 million. The revenue decline primarily reflected a $21.2 million decrease in ZOLGENSMA royalties, largely due to U.S. licensed-patent expirations; $2.8 million of ITVISMA royalties partly offset it. The quarter included a $38.0 million gain from the Sarepta settlement; its $39.0 million payment was received in October, net of amounts payable to licensors.
Cash, cash equivalents and marketable securities were $251.0 million as of September 30, 2026. The company expects that balance, together with the $39.0 million settlement payment received in October, to fund operations into late Q4 2027 under current plans; guidance excludes material potential partner or licensee milestone payments and additional funding opportunities.
RGX-202’s BLA submission remains on track for Q1 2027, with potential accelerated approval in 2H 2027. Topline data from pivotal wet AMD trials are expected in Q4 2026. The FDA placed RGX-121 on clinical hold in August 2026 after asymptomatic spine MRI findings in five CAMPSIITE participants; REGENXBIO continues collecting and evaluating imaging and long-term follow-up data.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly net loss narrowed to $40.7 million from $61.9 million.
Negative
- Moderate pointQuarterly revenue fell to $9.2 million from $29.7 million.
- Moderate pointRGX-121 clinical hold followed MRI findings in five participants.
Filing Explained
REGENXBIO reports a completed July underwritten offering of common stock and pre-funded warrants that generated
8-K Event Classification
Key Figures
Key Terms
Biologics License Application (BLA) regulatory
accelerated approval pathway regulatory
subretinal delivery medical
prophylactic topical steroids medical
Earnings Snapshot
The $251.0 million balance as of September 30, 2026, together with $39.0 million in settlement proceeds received in October 2026, is expected to fund operations into late Q4 2027 under current operational plans. The guidance excludes material potential partner or licensee milestone payments and additional dilutive or non-dilutive funding opportunities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were RGNX’s third-quarter 2026 revenue and net loss?
How long does RGNX expect its cash to fund operations?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: ( |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on Form 8‑K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Press release dated November 5, 2026 relating to REGENXBIO Inc.’s financial results. |
|
|
|
104 |
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
REGENXBIO INC. |
|
|
|
|
Date: |
November 5, 2026 |
By: |
/s/ Patrick J. Christmas II |
|
|
|
Patrick J. Christmas II
|
EXHIBIT 99.1
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., November 5, 2026 (PR Newswire) -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2026.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028,” said Curran Simpson, President and Chief Executive Officer of REGENXBIO. “With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”
PROGRAM HIGHLIGHTS AND MILESTONES
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to address the underlying cause of Duchenne by enabling targeted expression of a novel microdystrophin that is closest to naturally occurring dystrophin. The differentiated therapeutic approach behind RGX-202 includes a novel construct, with the C-Terminal domain, a proactive immune suppression regimen, and a suspension-based manufacturing process that delivers industry-leading product purity levels. RGX-202 is designed for improved muscle function, durability and positive safety outcomes and is being evaluated in the Phase I/II/III AFFINITY DUCHENNE® trial and confirmatory trial in ambulatory patients aged 1+.
Retinal Disease: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed in collaboration with AbbVie, is potentially the first-in-class gene therapy treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Sura-vec for the Treatment of Wet AMD (Subretinal Delivery)
Sura-vec for the Treatment of DR (Suprachoroidal Delivery)
Neurodegenerative Disease: RGX-121 (clemidsogene lanparvovec) is a potential first-in-class treatment for MPS II, also known as Hunter syndrome, being developed and potentially commercialized in partnership with Nippon Shinyaku.
FINANCIAL RESULTS
Cash Position: Cash, cash equivalents and marketable securities were $251.0 million as of September 30, 2026, compared to $240.9 million as of December 31, 2025. The increase was primarily attributable to a $100.0 million milestone payment received from AbbVie in July 2026 for the dosing of the first patient in the Phase IIb/III NAAVIGATE study and net proceeds of $107.8 million from an underwritten public offering of common stock and pre-funded warrants completed in July 2026, and was partially offset by cash used to fund operating activities during the nine months ended September 30, 2026. Cash, cash equivalents and marketable securities as of September 30, 2026 excludes a $39.0 million payment received in October 2026 pursuant to a settlement agreement with Sarepta Therapeutics.
Revenues: Revenues were $9.2 million for the three months ended September 30, 2026, compared to $29.7 million for the three months ended September 30, 2025. The decrease was primarily attributable to ZOLGENSMA® royalty revenues, which decreased by $21.2 million due primarily to the expiration of licensed patents in the U.S. in January 2026. The decrease was partially offset by ITVISMA® royalty revenues of $2.8 million for the third quarter of 2026. Novartis launched U.S. sales of ITVISMA in the first quarter of 2026. ITVISMA is now also approved in the EU, Japan and multiple Gulf countries. REGENXBIO is entitled to royalties on certain net sales of ITVISMA in the U.S. and other jurisdictions with patents extending until 2037.
Research and Development (R&D) Expenses: R&D expenses were $61.0 million for the three months ended September 30, 2026, compared to $56.1 million for the three months ended September 30, 2025. The increase was primarily attributable to clinical trial expenses for RGX-202.
General and Administrative (G&A) Expenses: G&A expenses were $20.6 million for the three months ended September 30, 2026, consistent with $20.3 million for the three months ended September 30, 2025.
Gain on Litigation Settlement: REGENXBIO recorded a gain of $38.0 million in the third quarter of 2026 related to a settlement agreement with Sarepta Therapeutics to resolve all patent litigation matters between the parties. The gain consisted of a $39.0 million settlement payment due from Sarepta, net of proceeds payable to certain licensors as a result of the settlement. The $39.0 million settlement payment was received from Sarepta in October 2026.
Net Loss: Net loss was $40.7 million, or $0.62 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to a net loss of $61.9 million, or $1.20 basic and diluted net loss per share, for the three months ended September 30, 2025.
FINANCIAL GUIDANCE
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $251.0 million as of September 30, 2026, along with the $39.0 million settlement proceeds received in October 2026, are sufficient to fund operations into late Q4 2027. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes any additional potential dilutive or non-dilutive funding opportunities.
CONFERENCE CALL
In connection with this announcement, REGENXBIO will host a conference call and webcast at 8:00 a.m. ET today. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such
words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC) and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ZOLGENSMA® and ITVISMA® are registered trademarks of Novartis. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
REGENXBIO INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands)
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
95,795 |
|
|
$ |
34,466 |
|
Marketable securities |
|
|
155,181 |
|
|
|
195,604 |
|
Accounts receivable |
|
|
8,536 |
|
|
|
26,379 |
|
Prepaid expenses |
|
|
13,009 |
|
|
|
11,927 |
|
Restricted cash |
|
|
225 |
|
|
|
— |
|
Other current assets |
|
|
48,146 |
|
|
|
12,905 |
|
Total current assets |
|
|
320,892 |
|
|
|
281,281 |
|
Marketable securities |
|
|
— |
|
|
|
10,785 |
|
Accounts receivable |
|
|
450 |
|
|
|
2,312 |
|
Property and equipment, net |
|
|
95,347 |
|
|
|
104,855 |
|
Operating lease right-of-use assets |
|
|
42,246 |
|
|
|
47,156 |
|
Restricted cash |
|
|
1,805 |
|
|
|
2,030 |
|
Other assets |
|
|
5,300 |
|
|
|
4,613 |
|
Total assets |
|
$ |
466,040 |
|
|
$ |
453,032 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
13,482 |
|
|
$ |
21,358 |
|
Accrued expenses and other current liabilities |
|
|
29,611 |
|
|
|
38,390 |
|
Deferred revenue |
|
|
5,985 |
|
|
|
10,452 |
|
Operating lease liabilities |
|
|
6,492 |
|
|
|
8,286 |
|
Royalty monetization liabilities |
|
|
12,114 |
|
|
|
39,609 |
|
Total current liabilities |
|
|
67,684 |
|
|
|
118,095 |
|
Deferred revenue |
|
|
16,221 |
|
|
|
18,943 |
|
Operating lease liabilities |
|
|
60,054 |
|
|
|
65,215 |
|
Royalty monetization liabilities |
|
|
173,564 |
|
|
|
147,408 |
|
Other liabilities |
|
|
475 |
|
|
|
638 |
|
Total liabilities |
|
|
317,998 |
|
|
|
350,299 |
|
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock; no shares issued and outstanding |
|
|
— |
|
|
|
— |
|
Common stock; 66,119 and 50,892 shares issued |
|
|
7 |
|
|
|
5 |
|
Additional paid-in capital |
|
|
1,383,187 |
|
|
|
1,229,442 |
|
Accumulated other comprehensive loss |
|
|
(1,045 |
) |
|
|
(687 |
) |
Accumulated deficit |
|
|
(1,234,107 |
) |
|
|
(1,126,027 |
) |
Total stockholders’ equity |
|
|
148,042 |
|
|
|
102,733 |
|
Total liabilities and stockholders’ equity |
|
$ |
466,040 |
|
|
$ |
453,032 |
|
REGENXBIO INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except per share data)
|
|
Three Months |
|
|
Nine Months |
|
||||||||||
|
|
Ended September 30, |
|
|
Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
License and royalty revenue |
|
$ |
5,244 |
|
|
$ |
23,605 |
|
|
$ |
114,175 |
|
|
$ |
129,119 |
|
Service revenue |
|
|
3,918 |
|
|
|
6,128 |
|
|
|
9,399 |
|
|
|
10,985 |
|
Total revenues |
|
|
9,162 |
|
|
|
29,733 |
|
|
|
123,574 |
|
|
|
140,104 |
|
Operating Expenses (Income) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of license and royalty revenues |
|
|
1,141 |
|
|
|
5,725 |
|
|
|
13,257 |
|
|
|
14,370 |
|
Research and development |
|
|
61,009 |
|
|
|
56,101 |
|
|
|
174,434 |
|
|
|
168,688 |
|
General and administrative |
|
|
20,579 |
|
|
|
20,253 |
|
|
|
63,501 |
|
|
|
60,483 |
|
Gain on litigation settlement |
|
|
(38,026 |
) |
|
|
— |
|
|
|
(38,026 |
) |
|
|
— |
|
Other operating expenses (income) |
|
|
(7 |
) |
|
|
65 |
|
|
|
41 |
|
|
|
125 |
|
Total operating expenses |
|
|
44,696 |
|
|
|
82,144 |
|
|
|
213,207 |
|
|
|
243,666 |
|
Loss from operations |
|
|
(35,534 |
) |
|
|
(52,411 |
) |
|
|
(89,633 |
) |
|
|
(103,562 |
) |
Other Income (Expense) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income from licensing |
|
|
16 |
|
|
|
19 |
|
|
|
49 |
|
|
|
65 |
|
Investment income |
|
|
2,252 |
|
|
|
3,620 |
|
|
|
5,477 |
|
|
|
9,500 |
|
Interest expense |
|
|
(7,472 |
) |
|
|
(13,169 |
) |
|
|
(23,973 |
) |
|
|
(32,732 |
) |
Total other income (expense) |
|
|
(5,204 |
) |
|
|
(9,530 |
) |
|
|
(18,447 |
) |
|
|
(23,167 |
) |
Net loss |
|
$ |
(40,738 |
) |
|
$ |
(61,941 |
) |
|
$ |
(108,080 |
) |
|
$ |
(126,729 |
) |
Other Comprehensive Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized gain (loss) on available-for-sale securities, net |
|
|
(170 |
) |
|
|
98 |
|
|
|
(358 |
) |
|
|
89 |
|
Total other comprehensive income (loss) |
|
|
(170 |
) |
|
|
98 |
|
|
|
(358 |
) |
|
|
89 |
|
Comprehensive loss |
|
$ |
(40,908 |
) |
|
$ |
(61,843 |
) |
|
$ |
(108,438 |
) |
|
$ |
(126,640 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share, basic and diluted |
|
$ |
(0.62 |
) |
|
$ |
(1.20 |
) |
|
$ |
(1.90 |
) |
|
$ |
(2.46 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
65,263 |
|
|
|
51,689 |
|
|
|
56,884 |
|
|
|
51,513 |
|